Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
作者信息
Kander Elizabeth M, Shah Manisha H, Zhou Ye, Goyal Ashima, Palmer Joshua D, Owen Dwight H, Shilo Konstantin, Patel Gopal, Raval Raju R, Gonzalez Javier, Nguyen Michele, Olek Elizabeth, Kherani Jennifer, Rothenberg S Michael, Konda Bhavana
机构信息
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
出版信息
Clin Lung Cancer. 2021 May;22(3):e442-e445. doi: 10.1016/j.cllc.2020.06.011. Epub 2020 Jun 18.
PMID:32660930
Abstract
摘要
Zotero 插件